(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/212618 A1

(51) International Patent Classification:
A61K 9/51 (2006.01) *A61K 31/70* (2006.01)
A61K 31/00 (2006.01)

(21) International Application Number:
PCT/US2023/066266

(22) International Filing Date:
26 April 2023 (26.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/335,092 26 April 2022 (26.04.2022) US

(71) Applicant: **STRAND THERAPEUTICS INC.** [US/US]; 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US).

(72) Inventors: **SOWELL, Ryan**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **BOOTHELLO, Rio**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **ABRHAM, Wuhbet**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **ZHAO, Weiyu**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **MENON, Nandita**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **SHAH, Aalok**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **NAMBIAR, Prashant**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US). **KITADA, Tasuku**; c/o STRAND THERAPEUTICS INC., 20 Overland Street, Suite A, Boston, Massachusetts 02215 (US).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF

(57) Abstract: The present disclosure relates to lipid nanoparticles (LNPs) comprising VEE replicon, wherein the LNPs are useful for selectively reducing and/or avoiding the expression of a payload within the liver. The present disclosure also relates to the use of such LNPs to treat various diseases and disorders.

WO 2023/212618 A1